Catalyst Brief

← Calendar

Readoutin 45d

Ocular Therapeutix, Inc. — OTX-TKI

Phase 3 primary completion: Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration.

Date
Jan 2027
Type
Readout
Indication
Neovascular Age-related Macular Degeneration

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.